Drug and treatment developer M Pharmaceutical Inc (CSNX:MQ, OTCMKTS:MPHMF) now expects to launch its fertility product 'ToConceive' to the North American market this September, sending shares surging..
Shares rose 8% yesterday and are up over 14% to $0.08 at the time of writing in Toronto today.
FDA cleared product...
It is an FDA - cleared over-the-counter product, and M Pharma brought the global marketing rights to it last November.
It then contracted Anstice Communications (Anstice) based in Calgary. This is a leading integrated communications agencies, which has developed new branding, packaging and a website for ToConceive.
"Anstice is proud to partner with M Pharmaceuticals as it introduces ToConceive to the market," said Sheenah Rogers, its founder and chief executive.
"We will be working closely with M Pharma to implement an effective brand strategy and build strong awareness of this innovative new product among consumers."
ToConceive is a natural conception aid that balances pH values to support sperm survival and gives it (wperm) the ability, or capacity, to fertilize the ovum- a process called sperm capacitation.
"As someone who endured a long and costly fertility journey (emotional, physical and financial), I'm optimistic about any non-invasive option that can help address fertility related issues and do so much earlier in the journey," said Kim Whittemore, a women's sexual health advocate and board member of M Pharma.
"The science behind ToConceive is sound and will help many couples avoid more expensive and invasive treatments."
Raised revenue guidance...
Last Friday, M Pharmaceutical Inc shares shot up as it raised its revenue guidance for this quarter and the next.
It came after the firm looked at its order books and factored in planned product launches from its established distribution partners, including branded product launches in the USA and Canada, plus sales to new distribution/marketing partners outside of North America.
M Pharma was recently informed that one of its customers has received new product approvals in new foreign markets, both in the Americas and in Asia, and will be launching operations in those markets in the third quarter and fourth quarter of 2017.
In addition to the expansion into new markets, M Pharma is in late-stage discussions with some current business partners for the sale of newly developed topical formulations of its menthol and L-arginine technology, in multiple topical formats (e.g. skin patches) for a variety of treatment conditions.
M Pharma has plans to launch multiple new branded products in numerous sales channels in the United States and Canadian markets in the third quarter and fourth quarter of 2017, with additional product line launches in 2018 to advance top-line revenues and profitability.
These multiple pipeline products were acquired from 40J's LLC earlier this year and represent only a sample of the technologies currently working their way to commercialization, the company said.